Understanding resistance to endocrine agents: Molecular mechanisms and potential for intervention

Clinical Breast Cancer

Volumn 10, Issue 1, 2010, Pages

  Sabnis, Gauri ^a   Brodie, Angela ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Estrogen receptor; HER2; Letrozole; LTLT Ca; MAPK; MCF 7Ca; Tamoxifen; Trastuzumab

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER RESISTANCE; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ESTROGEN SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVARIECTOMY; POSTMENOPAUSE; PREDICTIVE VALIDITY; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 76949089720     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.014     Document Type: Review

References (33)

1. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004; 96:456-465
2. Yue W, Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 1993; 44:671-673
3. Yue W, Zhou D, Chen S, et al. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 1994; 54:5092-5095
4. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990; 50:6949-6954
5. Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published erratum in: N Engl J Med 2006; 354:2200]. N Engl J Med 2005; 353:2747-2757
6. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial [published erratum in: Lancet 2002; 360:1520]. Lancet 2002; 359:2131-2139
7. Goss PE. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin Oncol 2006; 33(suppl 7):S8-12.
8. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-1802
10. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [published errata in: N Eng J Med 2004; 351:2461 and N Engl J Med 2006; 355:1746]. N Engl J Med 2004; 350:1081-1092
11. Long BJ, Jelovac D, Thiantanawat A, et al. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 2002; 8:2378-2388
12. Jelovac D, Sabnis G, Long BJ, et al. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005; 65:5380-5389
13. Sabnis G, Schayowitz A, Goloubeva O, et al. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009; 69:1416-1428
14. Sabnis GJ, Jelovac D, Long B, et al. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005; 65:3903-3910
15. Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 2008; 68:4518-4524
16. Sabnis G, Goloubeva O, Jelovac D, et al. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. Clin Cancer Res 2007; 13:2751-2757
17. Long BJ, Tilghman SL, Yue W, et al. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998; 67:293-304.
18. Yue W, Wang J, Savinov A, et al. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995; 55:3073-3077
19. Goss PE, Gwyn KM. Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994; 12:2460-2470
20. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet 2005; 366:431-433
21. Sabnis G, Brodie A. Trastuzumab improves the responsiveness of letrozole refractory human breast cancer cells to endocrine therapy. Presented at: the 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX. Abstract 109.
22. Sabnis GJ, Schayowitz A, Goloubeva O, et al. Trastuzumab increases sensitivity of hormone dependent and hormone refractory breast cancer cells to endocrine agents. Presented at: the 98th AACR Annual Meeting; April 14-18, 2007; Los Angeles, CA. Abstract 991.
23. Johnston SR, Head J, Pancholi S, et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003; 9:524S-32S.
24. Yue W, Wang JP, Conaway MR, et al. Adaptive hypersensitivity following longterm estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol 2003; 86:265-274
25. Santen RJ, Song RX, McPherson R, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80:239-256
26. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen- activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141:396-405.
27. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11:865s-70s.
28. Oh AS, Lorant LA, Holloway JN, et al. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001; 15:1344-1359
29. Creighton CJ, Hilger AM, Murthy S, et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res 2006; 66:3903-3911
30. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7(12 suppl):4436s-4442s; discussion 4411s-4412s.
31. Wang CX, Koay DC, Edwards A, et al. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer. Breast Cancer Res Treat 2005; 92:251-263
32. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96:926-935
33. Johnston SR, Leary A, Martin LA, et al. Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise? Cancer 2008; 112(3 suppl):710-717